Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.35 |
| ▸ | CHRNG | P07510 | 1/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.35 |
| ▸ | CHRND | Q07001 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 3/20 | 0.34 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.34 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22138373 | 0.93 | FURIN (0.45) | FURINHTTSMN1; SMN2CHRNA1CHRNG | |
| SCHEMBL24916488 | 0.92 | FURIN (0.48) | FURINHTTSMN1; SMN2CHRNA1CHRNG | |
| SCHEMBL22138371 | 0.91 | FURIN (0.44) | FURINHTTCHRNA1CHRNGCHRNB1 | |
| SCHEMBL25831637 | 0.88 | HTT (0.41) | FURINHTTSMN1; SMN2CHRNA1CHRNG | |
| SCHEMBL30297062 | 0.87 | HTT (0.41) | FURINHTTSMN1; SMN2CHRNA1CHRNG | |
| SCHEMBL21883412 | 0.87 | FURIN (0.42) | FURINHTTSMN1; SMN2CHRNA1CHRNG | |
| SCHEMBL24916473 | 0.87 | FURIN (0.42) | FURINHTTSMN1; SMN2CHRNA1CHRNG | |
| SCHEMBL19591557 | 0.86 | FURIN (0.49) | FURINHTTCHRNA1CHRNGCHRNB1 | |
| SCHEMBL25726157 | 0.86 | CHRND (0.41) | FURINHTTCHRNA1CHRNGCHRNB1 | |
| SCHEMBL25726153 | 0.86 | CHRND (0.41) | FURINHTTCHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | Regeneran Pharmaceuticals, Inc. (US) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | ASGR1, CUTA, SRPRA | FURIN 794/4885HTT 4160/4885SMN1; SMN2 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.